Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company developing therapies for oncology and obesity. Its pipeline includes CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting Nectin-4 for the treatment of advanced solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. The company holds a license from CSPC Megalith Biopharmaceutical Co. Ltd. to develop and commercialize CRB-701 in the United States, Canada, the European Union, the United Kingdom, and Australia. CRB-701 is currently in Phase 1/2 clinical trials in the U.S. and Europe, with a Phase 3 trial being conducted by CSPC in China. The company also develops CRB-913, an oral cannabinoid type-1 receptor inverse agonist for the treatment of obesity, which is in Phase 1 clinical trials in the United States. Corbus was founded in 2009.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage corbuspharma.com
Sector Healthcare IR page ir.corbuspharma.com
Tags
oncology, obesity, antibody-drug conjugates, cannabinoid receptor inverse agonists, solid tumors, cervical cancer, head and neck cancer, urothelial cancer, metabolic disease, clinical-stage, CRB-701, SYS6002, CRB-913, CSPC Megalith Biopharmaceutical Co. Ltd., CSPC Pharmaceutical Group Limited, Keytruda, pembrolizumab, PADCEV, enfortumab vedotin, CANYON-1, TEMPO-1
Press page ir.corbuspharma.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 84.5M
Market cap (USD) $ 84.5M
P/E -0.68
PEG —
P/BV 1.00
P/S 95.84
P/OCF -0.91
P/FCF -1.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -54.2%
ROI -66.0%
ROIC -53.8%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 67
Quality score -68.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue — — — 0 881.705K 3.937M 36.144M 4.822M 2.44M 1.911M 648.382K — —
Net profit -78.537M -40.209M -44.603M -42.347M -45.64M -111.269M -71.454M -55.672M -32.422M -19.999M -8.851M -2.54M -602.35K
Free cash flow -64.498M -41.794M -36.1M -37.558M -48.238M -100.17M -48.463M -32.368M -28.504M -13.924M -4.762M -2.426M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 8.14 11.8 6.04 0.11 0.62 1.25 5.46 5.84 7.1 8.45 1.65 3.36 —
Price performance 12m -0.31 0.95 53.66 -0.82 -0.51 -0.77 -0.07 -0.18 -0.16 4.13 -0.51 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — — 3.09M 2.8M 15.9M — —
Borrowings, non-current (USD) — — — — 18M 15.6M 16M 0.00 — —
Lease liabilities (USD) — — 1.41M 8.69M 8.1M 7.09M 5.96M 4.68M 3.24M 1.63M
Cash and deposits (USD) 15M 62.5M 41.7M 31.7M 85.4M 25M 17M 13.7M 17.2M 28.5M
Right-of-use assets (USD) — — 2.4M 5.82M 5.25M 4.61M 3.88M 3.06M 2.13M 1.08M
Net debt (borrowings + leases - cash) (USD) — — — — -59.3M 816,152 7.73M 6.86M — —
Cash flow detail
Operating cash flow (USD) -13.6M -27.8M -30.1M -45.7M -99.7M -48.2M -37.5M -36.1M -41.8M -64.5M
Purchases of property, plant and equipment (USD) -353,032 -707,429 -2.3M -2.74M -484,491 -54,172 -13,449 0.00 0.00 -7,000
Change in receivables (cash effect) (USD) -1M 1M 12.5M 5M — — — — — —
Change in payables (cash effect) (USD) 1.89M -885,797 3.9M 4.37M -3.47M -5.96M -256,835 1.03M 1.6M -2.35M
Interest paid (cash effect) (USD) -5,586 -12,377 -10,437 -29,448 -629,146 -1.74M -1.97M -2.61M -2.82M 0.00
Share-based compensation (USD) 3.16M 5.69M 7.61M 12M 12.5M 9.48M 5.72M 3.47M 6.15M 6.29M
Operating cash flow before change in receivables (USD) -12.6M -28.8M -42.6M -50.7M — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -13.9M -28.5M -32.4M -48.5M -100M -48.2M -37.6M -36.1M -41.8M -64.5M
Income detail
Research and development expense (USD) 15.4M 26M 48.6M 89.6M 98.3M 36.4M 16.1M 31.2M 32.2M 70.1M
↳ 5y CAGR +196.9% +134.8% +75.6% +18.7% -9.1% -8.5% -18.5% -6.5%
Total comprehensive income (USD) — — — — -111M -45.7M -42.4M -44.5M -40.2M -78.6M
Comprehensive income to owners (USD) — — — — -111M -45.7M -42.4M -44.5M -40.2M -78.6M
Reported Mar 8, 2017 Mar 12, 2018 May 9, 2019 Mar 16, 2020 Mar 8, 2022 Mar 8, 2022 Mar 7, 2023 Mar 12, 2024 Mar 9, 2026 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed

•Corresponding significant reductions were also seen in waist circumference and body mass index (BMI)

•Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data

•No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression

•Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s

NORWOOD, MA, November 16, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, announced today that additional data from the CANYON-1 Phase 1b obesity study were presented in a poster at ObesityWeek® 2026 (link: https://www.corbuspharma.com/sites/default/files/2026-11/Bays_ObesityWeek_SUBMITTED_30Oct26_DIGITAL_ONLY.pdf).

oDosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer

oReported topline data from the CANYON-1 Phase 1b obesity study of CRB-913 demonstrating mean weight loss of 5% after 12 weeks at 60 mg daily dose with no plateau observed and favorable safety and tolerability

oLate-breaking CANYON-1 data to be presented at ObesityWeek® 2026 on Saturday, November 15, 2026

Norwood, MA, November 10, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 third quarter ended September 30, 2026.

"During the third quarter, we achieved key milestones with both clinical programs: initiating dosing in our TEMPO-1 Phase 3 study of sutantatug envedotin in oropharyngeal cancer and announcing positive topline data from our CANYON-1 Phase 1b study of CRB-913 in obesity,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

November 05, 2026 8:00 am EST Download as PDF

NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and meet with investors at the following conferences during the month of November:

Scroll to view ↔

Guggenheim 3****rd Annual Healthcare Innovation Conference
Format: Presentation and one-on-one investor meetings
Date: Monday, November 9, 2026
Time: 8:00am EST
Webcast: Click here
Jefferies Global Healthcare Conference
Format: Fireside Chat and one-on-one investor meetings
Date: Wednesday, November 18, 2026
Time: 9:00am GMT
Webcast: Click here
9****th Annual Evercore Healthcare Conference
Format: Fireside Chat and one-on-one investor meetings
Date: Tuesday, December 1, 2026
Time: 10:25am EST
Webcast: Click here

Investors interested in meeting with Dr. Cohen should contact their representative.

About Corbus 
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on X , LinkedIn  and Facebook .

**Forward-Looking Statements
**This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated regulatory interactions and outcomes, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
[email protected]

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
[email protected]

Primary Logo

Source: Corbus Pharmaceuticals Holdings, Inc.

Released November 5, 2026

©2026 Corbus Pharmaceuticals Holdings, Inc. All Rights Reserved.

Prompts

Corbus Pharmaceuticals Holdings, Inc. (ticker CRBP), listed in United States.

Company History

Date Change Detail
Mar 12, 2014 Renamed SAV Acquisition Corp → CORBUS PHARMACEUTICALS HOLDINGS, INC.

ETFs Holding Corbus Pharmaceuticals Holdings, Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 99,983 $ 340.942K Nov 12, 2026
DXUV 0.00% 10,713 $ 36.531K Nov 12, 2026
DCOR 0.00% 18,707 $ 63.791K Nov 12, 2026
DFAC 0.00% 6,180 $ 21.074K Nov 12, 2026
AVSC 0.00% 26,976 $ 91.044K Nov 16, 2026